Literature DB >> 9011582

Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients.

G Garibotto1, A Barreca, R Russo, A Sofia, P Araghi, A Cesarone, M Malaspina, F Fiorini, F Minuto, A Tizianello.   

Abstract

To assess the effect of recombinant human growth hormone (rhGH) on muscle protein metabolism in uremic patients with malnutrition, forearm [3H]phenylalanine kinetics were evaluated in six chronically wasted (body weight 79% of ideal weight) hemodialysis (HD) patients in a self-controlled, crossover study. Forearm protein dynamics were evaluated before, after a 6-wk course of rhGH (5 mg thrice weekly) and after a 6-wk washout period. After rhGH: (a) forearm phenylalanine net balance--the difference between phenylalanine incorporation into and phenylalanine release from muscle proteins--decreased by 46% (-8+/-2 vs. -15+/-2 nmol/min x 100 ml at the baseline and -11+/-2 after washout, P < 0.02); (b) phenylalanine rate of disposal, an index of protein synthesis, increased by 25% (25+/-5 vs. 20+/-5 at the baseline and 20+/-4 after washout, P < 0.03); (c) phenylalanine rate of appearance, an index of protein degradation, was unchanged (33+/-5 vs. 35+/-5 at the baseline and 31+/-4 after washout); (d) forearm potassium release declined (0.24+/-0.13 vs. 0.60+/-0.15 microeq/min at the baseline, and 0.42+/-0.20 microeq/min after washout P < 0.03); (e) changes in the insulin-like growth factor binding protein (IGFBP)-1 levels and insulin-like growth factor-I (IGF-I)/IGFBP-3 ratios accounted for 15.1% and 47.1% of the percent variations in forearm net phenylalanine balance, respectively. Together, these two factors accounted for 62.2% of variations in forearm net phenylalanine balance during and after rhGH administration. These data indicate: (a) that rhGH administration in malnourished hemodialysis patients is followed by an increase in muscle protein synthesis and by a decrease in the negative muscle protein balance observed in the postabsorptive state; and (b) that the reduction in net protein catabolism obtained with rhGH can be accounted for by the associated changes in circulating free, but not total, IGF-I levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9011582      PMCID: PMC507772          DOI: 10.1172/JCI119139

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  ROLES OF INSULIN AND GROWTH HORMONE, BASED ON STUDIES OF FOREARM METABOLISM IN MAN.

Authors:  K L ZIERLER; D RABINOWITZ
Journal:  Medicine (Baltimore)       Date:  1963-11       Impact factor: 1.889

2.  Effect of insulin on carbohydrate metabolism and on potassium in the forearm of man.

Authors:  R ANDRES; M A BALTZAN; G CADER; K L ZIERLER
Journal:  J Clin Invest       Date:  1962-01       Impact factor: 14.808

3.  Influence of potassium on tissue protein synthesis.

Authors:  P R CANNON; L E FRAZIER; R H HUGHES
Journal:  Metabolism       Date:  1952-01       Impact factor: 8.694

4.  Cell-free studies of protein synthesis with skeletal muscle from normal and potassium-depleted rats.

Authors:  S D Alexis; G Vilaire; V R Young
Journal:  J Nutr       Date:  1971-02       Impact factor: 4.798

5.  Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle.

Authors:  S R Price; B K England; J L Bailey; K Van Vreede; W E Mitch
Journal:  Am J Physiol       Date:  1994-10

6.  Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism.

Authors:  D A Fryburg
Journal:  Am J Physiol       Date:  1994-08

7.  Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia.

Authors:  B Tönshoff; S Edén; E Weiser; B Carlsson; I C Robinson; W F Blum; O Mehls
Journal:  Kidney Int       Date:  1994-04       Impact factor: 10.612

8.  Short-term effects of recombinant human growth hormone in CAPD patients.

Authors:  T A Ikizler; R L Wingard; J A Breyer; G Schulman; R A Parker; R M Hakim
Journal:  Kidney Int       Date:  1994-10       Impact factor: 10.612

9.  The effects of human growth hormone (GH) administration in GH-deficient adults: a 20-day metabolic ward study.

Authors:  N K Valk; A J vd Lely; W W de Herder; J Lindemans; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

10.  Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes.

Authors:  K Brismar; E Fernqvist-Forbes; J Wahren; K Hall
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more
  8 in total

Review 1.  Mechanisms of muscle wasting in chronic kidney disease.

Authors:  Xiaonan H Wang; William E Mitch
Journal:  Nat Rev Nephrol       Date:  2014-07-01       Impact factor: 28.314

2.  The effect of insulin infusion upon protein metabolism in neonates on extracorporeal life support.

Authors:  Michael S D Agus; Patrick J Javid; Hannah G Piper; David Wypij; Christopher P Duggan; Daniel P Ryan; Tom Jaksic
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

3.  Mechanisms Regulating Muscle Protein Synthesis in CKD.

Authors:  Liping Zhang; Qin Chen; Zihong Chen; Ying Wang; Jorge L Gamboa; Talat Alp Ikizler; Giacomo Garibotto; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

4.  OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients.

Authors:  Joel D Kopple; Alfred K Cheung; Jens Sandahl Christiansen; Christian Born Djurhuus; Meguid El Nahas; Bo Feldt-Rasmussen; Martin Lange; William E Mitch; Christoph Wanner; Jonas Wiedemann; T Alp Ikizler
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

5.  Sarcopenia: a major challenge in elderly patients with end-stage renal disease.

Authors:  Maciej Domański; Kazimierz Ciechanowski
Journal:  J Aging Res       Date:  2012-03-28

6.  Wasting in chronic kidney disease.

Authors:  Robert H Mak; Alp T Ikizler; Csaba P Kovesdy; Dominic S Raj; Peter Stenvinkel; Kamyar Kalantar-Zadeh
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-03-16       Impact factor: 12.910

7.  Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial.

Authors:  Irene H Langbakke; Jakob N Nielsen; Mia P Skettrup; Angela Harper; Thomas Klitgaard; Angelika Weil; Eva Engelhardt; Martin Lange
Journal:  Clin Endocrinol (Oxf)       Date:  2007-07-18       Impact factor: 3.478

Review 8.  Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment.

Authors:  Varvara Chatzipetrou; Marie-Josée Bégin; Mélany Hars; Andrea Trombetti
Journal:  Calcif Tissue Int       Date:  2021-08-12       Impact factor: 4.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.